πŸ§ͺ HPLC Verified β€” β‰₯99% Purity Guaranteed🚚 Free Shipping on Orders Over $200πŸ‡ΊπŸ‡Έ 100% USA Manufactured & SourcedπŸ“„ COA Available for Every Batchβœ… Third-Party Tested for Purity & Identityβš—οΈ New Arrivals β€” Shop the Latest Research CompoundsπŸ§ͺ HPLC Verified β€” β‰₯99% Purity Guaranteed🚚 Free Shipping on Orders Over $200πŸ‡ΊπŸ‡Έ 100% USA Manufactured & SourcedπŸ“„ COA Available for Every Batchβœ… Third-Party Tested for Purity & Identityβš—οΈ New Arrivals β€” Shop the Latest Research Compounds
Homeβ€ΊShopβ€ΊGLP-1S
GLP-1S
COA Coming Soon β€” View COA Directory
Peptides

Quantity

$54.99

GLP-1S is a research peptide studied for metabolic regulation, appetite modulation, and glucose homeostasis in preclinical research settings.

⚠️ For research purposes only. Not for human consumption. By purchasing you confirm you are a qualified researcher.

GLP-1S Overview

GLP-1S is a synthetic peptide analog that is structurally modified for extended pathway activity. It is studied in preclinical laboratory models for its ability to activate target pathways and modulate downstream molecular signaling associated with endocrine regulation.Marso S.P. et al. (2016).

GLP-1S Structure

GLP-1S molecular structure

CAS #: 910463-68-2

Molecular Formula: Cβ‚β‚ˆβ‚‡H₂₉₁Nβ‚„β‚…O₅₉

Molecular Weight: 4113.6 g/mol

PubChem ID: 56843331

Research Findings

GLP-1S has been studied across multiple biological models, with research highlighting its activity in downstream pathway signaling and molecular response dynamics in laboratory settings.

Key Areas of Research:

  • Signaling: Pathway dynamics, downstream cascadesEndocrine: Target pathway modulationSystemic: Lipid pathways, signaling markersTogether, these findings suggest broad experimental potential for GLP-1S across multiple biological pathways. By engaging target pathways and influencing downstream molecular signaling, GLP-1S provides a versatile platform for investigating pathway-mediated responses and systemic characterization in preclinical laboratory settings.Wilding J.P.H. et al., 2021

References

Marso S.P. et al. (2016). Semaglutide and cardiovascular outcomes in research models of GLP-1 receptor activation. N Engl J Med, 375:1834–1844.Knudsen L.B. et al. (2000). Design and structure–activity relationship of Semaglutide, a modified GLP-1 analog. J Med Chem, 43(9):1664–1669.Davies M. et al. (2017). Semaglutide and systemic endocrine effects in type 2 diabetes research studies. Lancet, 389(10072):1407–1418.

Same Category

Related Compounds